Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mg
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sore Throat Due to a Common Cold
Conditions
Sore Throat Due to a Common Cold
Trial Timeline
Dec 1, 2010 → Apr 1, 2011
NCT ID
NCT01265446About Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mg
Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mg is a phase 3 stage product being developed by Novartis for Sore Throat Due to a Common Cold. The current trial status is completed. This product is registered under clinical trial identifier NCT01265446. Target conditions include Sore Throat Due to a Common Cold.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01265446 | Phase 3 | Completed |
Competing Products
5 competing products in Sore Throat Due to a Common Cold
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benzocaine 8 mg + Placebo | Johnson & Johnson | Phase 3 | 77 |
| Penciclovir + Placebo | Novartis | Approved | 85 |
| Diclofenac sodium gel 1% + Placebo | Novartis | Phase 3 | 77 |
| Angal S, topical spray [Menthol] + ANTI-ANGIN® FORMULA, topical metered spray | Sandoz Group | Phase 3 | 74 |
| Angal, lozenges [menthol], + ANTI-ANGIN® FORMULA | Sandoz Group | Phase 3 | 74 |